Loading...
Loading...
In a report published Friday, Jefferies & Company reiterated its Hold rating on Amedisys
AMED, but lowered its price target from $14.00 to $9.00.
Jefferies noted, “While we continue to believe that home nursing -- being the lowest-cost pre- and post-acute care option -- will have a key place in the continuum of care longer-term, AMED faces numerous near-term headwinds that will pressure its earnings outlook and the stock's valuation. Until these challenges dissipate, we recommend that investors stay on the sidelines.”
Amedisys closed on Thursday at $10.50.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in